Thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
== Formation == Initial funding for the formation of Onyx came from biotechnology firm Chiron Corporation (granted a 43% stake in the new company) and venture capital investors: Avalon Ventures, Institutional Venture Partners (IVP), J. H. Whitney & Company and Kleiner Perkins. McCormick had been working on cancer treatments at Chiron before he was selected as vice president of research at the newly formed company, leading the company's research program. The acting president of the firm at its inception was Samuel D. Colella, a partner at early investor, IVP.
== One Health approach == Antimicrobial resistance (AMR) is commonly described within a One Health framework, which emphasizes the interconnected relationships between human health, animal health, and the environment. Antimicrobial use in clinical medicine, veterinary practice, and agriculture has been associated with the selection and spread of resistant microorganisms across these sectors. Research indicates that resistant bacteria and antimicrobial resistance genes can move between humans, animals, and environmental reservoirs through multiple pathways, including food production systems, direct contact, and exposure to contaminated water or soil. These pathways contribute to the persistence and wider dissemination of antimicrobial resistance beyond individual settings. Environmental sources have been increasingly examined in relation to AMR. Wastewater systems, agricultural runoff, and pharmaceutical residues have been identified as potential reservoirs where resistant microorganisms and resistance genes may persist. Such reservoirs may facilitate ongoing transmission between environmental, animal, and human populations. Efforts to address AMR within a One Health framework typically involve coordinated strategies across sectors, including antimicrobial stewardship, infection prevention and control, and improvements in sanitation and hygiene.
== Roles within biomedical science == A sub-set of biomedical sciences is the science of clinical laboratory diagnosis. This is commonly referred to in the UK as 'biomedical science' or 'healthcare science'. There are at least 45 different specialisms within healthcare science, which are traditionally grouped into three main divisions:
== Research == Treatments for ATTR-related neuropathy include TTR-specific oligonucleotides in the form of small interfering RNA (patisiran) or antisense inotersen, the former having recently received FDA approval. Research into treatments for ATTR amyloidosis have compared liver transplantation, oral drugs that stabilize the misfolding protein (including tafamidis and diflunisal), and newer therapeutic agents still being investigated (including patisiran). Based on available research, liver transplant remains the most effective treatment option for advanced ATTR amyloidosis, protein stabilizing drugs may slow disease progression but were insufficient to justify delay of liver transplant, and newer agents such as patisiran require additional studies.
Sources: en.wikipedia.org
6 RCN + 4 (NSCl)3 → 6 [RCN2S2]+Cl− + 3 Cl2 + 3 N2 Sulfur trioxide successively oxidizes the compound at the sulfur atoms to (NSOCl)3. The latter is also the pyrolysis product of a mixture of phosphorus pentachloride and sulfamic acid. In principle, it exists as stereoisomers, but only one (all chlorides axial) had been isolated by 1979.
The ineffectual response was caused by feuding officials who refused to co-operate with each other contributed to the death toll. It took weeks for aid to reach some villages, causing much resentment in Calabria. To offset widespread criticism that the government in Rome did not care about Calabria, King Victor Emmanuel III personally took over the relief operation and toured the destroyed villages of Calabria, which won the government a measure of popularity. Notably, after the king took charge, the feuding ceased and aid started to flow.
Denmark is one of the twelve original founding member states of NATO, and signed the Greenland Defense Agreement with the United States in 1951, allowing the American military to operate in Greenland with Danish consent under a NATO framework. At its peak, approximately 10,000 American military personnel were stationed in Greenland, including about 6,000 at what is now Pituffik Space Base. After the Cold War, Greenland became a lower strategic priority for the United States, which gradually reduced its presence to roughly 150 personnel by 2026. After the September 11 attacks in 2001, Denmark supplied military aid to the United States as part of its NATO Article 5 obligation, incurring 44 deaths in the Afghan War. Denmark increased its Arctic defence and led a large NATO exercise in Greenland in 2025. The exercise involved more than 550 soldiers, including special forces, from Denmark, Norway, Sweden, France, and Germany. The Nordic countries also collaborate on Arctic defence through NATO exercises conducted across the region, such as the Joint Viking exercise in 2025. In 2025, Denmark announced a 14.6 billion kr. plan to boost Arctic defence. Greenland is under the military command of the Joint Arctic Commander, Danish general Søren Andersen. The Arctic Command has around 150 permanent personnel, but regularly deploys units from across the Danish Defence forces, including the Arctic Response Force with aircraft and ships that stand ready to support forces in Greenland.
The initial contact between macrophage antigen-bound MHC II and TCR serves as the contact point between the two cells where most of the IFN-γ secretion and CD-40L on T cells concentrate to, so only macrophages directly interacting with TH1 cells are likely to be activated. In addition to activating M1 macrophages, TH1 cells express Fas ligand (FasL) and lymphotoxin beta (LT-β) to help kill chronically infected macrophages that can no longer kill pathogens. The killing of chronically infected macrophages release pathogens to the extracellular space that can then be killed by other activated macrophages. TH1 cells also help recruit more monocytes, the precursor to macrophages, to the infection site. TH1 secretion TNF-α and LT-α to make blood vessels easier for monocytes to bind to and exit. TH1 secretion of CCL2 as a chemoattractant for monocytes. IL-3 and GM-CSF released by TH1 cells stimulate more monocyte production in the bone marrow. When intracellular pathogens cannot be eliminated, such as in the case of Mycobacterium tuberculosis, the pathogen is contained through the formation of granuloma, an aggregation of infected macrophages surrounded by activated T cells. The macrophages bordering the activated lymphocytes often fuse to form multinucleated giant cells that appear to have increased antimicrobial ability due to their proximity to TH1 cells, but over time, the cells in the center start to die and form necrotic tissue.
== Physiology == A. parasiticus produces aflatoxins B1, B2, G1, and G2, named for the colours emitted under UV light on thin-layer chromatography plates—either blue and green. The numbers refer to the type of compound with 1 being major and 2 being minor. These aflatoxins are carcinogenic mycotoxins which have detrimental effects to humans and livestock. A. parasiticus also has the ability to produce kojic acid, aspergillic acid, nitropropionic acid and aspertoxin as secondary antimicrobial metabolites in response to different environments, all of which can be useful in identification. A. parasiticus also differs in sclerotia quantity number, volume, and shape. This fungus can be reliably identified using molecular methods. A. parasiticus produces aflatoxins at higher concentrations than A. flavus in temperatures ranging from 12–42 °C (54–108 °F) with pH ranging from 3 to greater than 8. Light exposure, oxidative growth conditions, fungal volatiles and nutrient availability (sugars and zinc) affect the production of these toxins. Greater zinc availability increases aflatoxin output. Environmental stress caused by drought and/or high temperatures during the latter part of the growing season of crops increases the likelihood of fungal growth. The aflatoxins produced by A. parasiticus are hazardous under normal food handling conditions and are especially stable when absorbed by starch or protein on the surfaces of seeds.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.